Outer membrane protein C (OMPC) epitope of Shigella flexneri 3a as a potential marker of primary immunodeficiencies (PID) and isolated anti-OmpC antibodies as a tool for immunoglobulin replacement therapy
The results demonstrate that the additional use of the cyclic/linear peptide-BSA conjugate offers a significant advantage over the use of the complete OmpC protein for immunological testing in PID diagnostics. Furthermore, specific anti-OmpC antibodies may be beneficial in the complementary therapy for patients with PIDS.
Authors
- Aleksandra Lewandowicz‐Uszyńska (ORCID: https://orcid.org/0000-0002-8876-021X)
- Ewa Masłowska
- Edyta Pawlak (ORCID: https://orcid.org/0000-0002-0386-7940)
- Andrzej Gamian (ORCID: https://orcid.org/0000-0002-2206-6591)
- Piotr Naporowski (ORCID: https://orcid.org/0000-0002-9412-5511)
- Danuta Witkowska (ORCID: https://orcid.org/0000-0003-3494-8724)
- Jacek Rybka (ORCID: https://orcid.org/0000-0003-4499-1574)
Institutions
- Wroclaw Medical University (PL)
- Łukasiewicz Research Network – PORT Polish Center for Technology Development (PL)
- Ludwik Hirszfeld Institute of Immunology and Experimental Therapy (PL)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-19
- DOI
- https://doi.org/10.3389/fimmu.2025.1701211
- Primary Topic
- Immunodeficiency and Autoimmune Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00